Lusatrombopag is an oral thrombopoietin receptor agonist (TPO-RA) used to treat adult patients with chronic liver disease and thrombocytopenia who plan to undergo surgery.

1、 Drug name

1. Common name: Lusatrombopag

2. Product Name: MULPLETA

2、 Indications

Used to treat thrombocytopenia in adult patients with chronic liver disease, suitable for patients planning to undergo surgery.

3、 Specifications and characteristics

1. Specification: 3mg/tablet

2. Appearance: Round film coated sheet.

4、 Main components

1. Active ingredient: Lusatrombopag

2. Accessories: D-mannitol, microcrystalline cellulose, magnesium oxide, sodium dodecyl sulfate, hydroxypropyl cellulose, etc.

5、 Usage and dosage

1. Recommended dosage: 3mg orally, once daily, taken continuously for 7 days.

2. Medication timing: Medication should be taken 8-14 days before surgery, and surgery should be performed within 2-8 days after the last dose.

3. Omission treatment: If missed, it should be taken as soon as possible on the same day and the normal medication plan should be resumed the next day.

6、 Dose adjustment

No special dosage adjustment instructions, limited to a 7-day course of treatment, and medication cannot be extended for "normalized platelet count".

7、 Medication precautions

1. Before and after meals: can be taken with food or on an empty stomach.

2. Vomiting: If vomiting occurs after taking the medication, there is no need to take it again, and continue taking the medication according to the original plan.

3. Monitoring: Platelet count should be measured within 2 days before medication and surgery.

8、 Medication for special populations

1. Pregnant women: No human data available, animal experiments show risks, need to weigh the pros and cons.

2. Breastfeeding period: Breastfeeding is prohibited during the treatment period and within 28 days after the last dose.

3. Children: Safety has not been established.

4. Elderly patients: There is no significant difference compared to younger patients.

9、 Adverse reactions

1. Most common: headache (≥ 3%).

2. Serious risk: Thrombosis/thromboembolic events (such as portal vein thrombosis).

10、 Contraindications

There are no clear contraindications, but caution should be exercised when there is a risk of thrombosis.

11、 Drug interactions

1. There is no significant effect when combined with cyclosporine (P-gp/BCRP inhibitor) or multivalent cationic antacids.

2. In vitro studies have shown that there is a low risk of inhibition of CYP enzymes, UGT enzymes, and common transporters.

12、 Storage method

1. Store in original packaging at a temperature of 20 ° C-25 ° C (15 ° C-30 ° C allowed).

2. Keep out of reach of children.

Lusutrombopaginformation